Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Aimmune Therapeutics, a US-based biopharma company developing treatments for life-threatening food allergies, has appointed Daniel Adelman its new chief medical officer. 23 June 2016
Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly-created position, at US pharma major Bristol-Myers Squibb, effective June 21, 2016. 22 June 2016
A former heavyweight at US health care giant Johnson & Johnson has been named in a key position with Biogen to lead the biotech company’s growth in development and manufacturing. 22 June 2016
Shares in British drugmaker GlaxoSmithKline (LON: GSK) fell some 2.35% in Tuesday trading, on the news that the company's vaccines boss, Moncef Slauoi, is to retire in June 2017. 15 June 2016
Shareholders of German family-owned pharma major Boehringer Ingelheim have decided to appoint Simone Menne to the firm’s board of managing directors with effect from September 1, 2016. 10 June 2016
The US District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen Therapeutics and Japan’s Takeda Pharmaceutical against Andrx and Actavis (now Allergan) companies. 10 June 2016
German family-owned drugmaker Grünenthal Group today announced that its supervisory board has named Gabriel Baertschi to become Grünenthal’s new chief executive as of October 1, 2016. 7 June 2016
Germany’s Merck (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) plan to file for accelerated approval of avelumab for the treatment of patients with metastatic merkel cell carcinoma (MCC), it has been revealed. 6 June 2016
Embattled drug company Valeant has named Tyco International executive Sam Eldessouky as corporate controller and a senior vice president as it tries rebuild its reputation after a string of controversies. 27 May 2016
US biotech Gilead Sciences has added two names to its senior leadership team, with Kevin Young taking on the chief operating officer role and Martin Silverstein becoming executive vice president for strategy. 25 May 2016
US drugmaker Ariad Pharmaceuticals has appointed Jennifer Herron as executive vice president, chief commercial officer, effective May 31, 2016. 25 May 2016
UK biotech Silence Therapeutics has announced a number of changes to its management as it positions itself as a leading RNA technology company. 25 May 2016
Olivier Brandicourt, chief executive of French pharma major Sanofi, announced today a number of changes to the company's executive committee. 23 May 2016
UK-based Proteome Sciences has said that Jeremy Haigh will be joining its board of directors as chief executive in June (subject to regulatory approval). 18 May 2016
Novartis late yesterday announced major changes to focus its Pharmaceuticals Division by creating two business units reporting to the chief executive: Novartis Pharmaceuticals and Novartis Oncology. 18 May 2016
Japanese pharma major Takeda Pharmaceutical has appointed James Kehoe as its new chief financial officer (CFO), hailing his ‘passion for transforming large organizations’ as key to the company’s growth ambitions. 16 May 2016